HS
CGEM icon

HighVista Strategies’s Cullinan Oncology CGEM Stock Holding History

HighVista Strategies’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-31,893
Closed -$240K – 153
2025
Q2 		$240K Hold
31,893
– – 0.09% 142
2025
Q1 		$241K Hold
31,893
– – 0.09% 142
2024
Q4 		$388K Hold
31,893
– – 0.14% 129
2024
Q3 		$534K Buy
+31,893
New +$566K 0.18% 125
2023
Q1 		– Sell
-79,918
Closed -$843K – 110
2022
Q4 		$843K Hold
79,918
– – 0.5% 60
2022
Q3 		$1.02M Buy
+79,918
New +$1.08M 0.59% 40

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

HighVista Strategies's CGEM Position: Q3 2025 in Review

HighVista Strategies sold out of Cullinan Oncology (CGEM) in Q3 2025, closing a stake of 31,893 shares — an estimated $240K sold.

HighVista Strategies first reported a position in CGEM in Q3 2022 and held it in 6 quarters. The position peaked at $1.02M in Q3 2022. 145 funds tracked by Wall St. Rank hold CGEM as of Q3 2025.

  • HighVista Strategies reported no remaining Cullinan Oncology position as of Q3 2025 after selling out during the quarter.
  • HighVista Strategies sold 31,893 Cullinan Oncology shares in Q3 2025, an estimated $240K.
  • HighVista Strategies first reported a position in Cullinan Oncology in Q3 2022 and held it in 6 quarters.
  • HighVista Strategies's Cullinan Oncology position peaked at $1.02M in Q3 2022.
  • 145 funds tracked by Wall St. Rank held Cullinan Oncology as of Q3 2025.

Based on HighVista Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.